v3.26.1
Equity Incentive Plan - Schedule of fair value of closing price of common stock on the date of the grant (Details) - USD ($)
1 Months Ended 2 Months Ended 6 Months Ended
Apr. 20, 2026
Jun. 30, 2026
Jun. 30, 2026
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of Shares Outstanding, Ending Balance   1,514,446 1,514,446
Weighted average remaining contractual term, Expected to vesting     2 years 10 days
Performance Stock Unit      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of Shares Outstanding, Beginning Balance [1]   1,109,394  
Granted   0  
Released   0  
Forfeitures and cancellations   0  
Number of Shares Outstanding, Ending Balance 1,109,394 [1] 1,109,394 1,109,394
Weighted Average Exercise Price, Beginning Balance [1]   $ 6.07  
Weighted average grant date fair value per share   0  
Weighted Average Exercise Price, Release   0  
Weighted Average Exercise Price, Forfeitures and cancellations   0  
Weighted Average Exercise Price, Ending Balance $ 6.07 [1] $ 6.07 $ 6.07
Weighted average remaining contractual term, Expected to vesting     2 years 7 months 17 days
Aggregate Intrinsic Value, Outstanding $ 2,220 [1] $ 2,030.00 $ 2,030.00
Restricted Stock Unit      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of Shares Outstanding, Beginning Balance [2]   1,514,446  
Granted   598,820  
Released   (57,402)  
Forfeitures and cancellations   0  
Number of Shares Outstanding, Ending Balance 1,514,446 [2] 2,055,864 2,055,864
RSU expected to vest at June 30, 2026   2,055,864 2,055,864
Weighted Average Exercise Price, Beginning Balance [2]   $ 17.62  
Weighted average grant date fair value per share   17.75  
Weighted Average Exercise Price, Release   12.95  
Weighted Average Exercise Price, Forfeitures and cancellations   0  
Weighted Average Exercise Price, Ending Balance $ 17.62 [2] 17.79 $ 17.79
Weighted average grant date, Expected to vest   $ 17.79 $ 17.79
Weighted-Average Remaining Contractual Term in years 1 year 7 months 2 days [2] 1 year 7 months 24 days  
Weighted average remaining contractual term, Expected to vesting   1 year 7 months 24 days 2 years 10 months 13 days
Aggregate Intrinsic Value, Outstanding $ 28,169,000 [2] $ 41,364,000 $ 41,364,000
Aggregate Intrinsic Value, Expected to vest   $ 41,364,000 $ 41,364,000
[1] As part of the Spin-Off, 1,109,394 substitute awards were issued related to awards from the AnaptysBio Equity Plan.
[2] As part of the Spin-Off, 1,514,446 substitute awards were issued related to awards from the AnaptysBio Equity Plan.